Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Telix Pharmaceuticals has announced the first Australian patient was dosed with TLX250-CDx (TLX) to help with kidney cancer at the Olivia Newton John Cancer and Wellness Centre (ONJ)
  • TLX is an antibody-based platform that targets carbonic anhydrase IX (aids in the conversion of carbon dioxide to carbonic acid)
  • Telix Pharmaceuticals is up 1.13 per cent today and is currently selling at $1.35 per share

Telix Pharmaceuticals has announced the first Australian patient has been dosed with TLX250-CDx (TLX) to help with kidney cancer at the Olivia Newton John Cancer and Wellness Centre (ONJ).

TLX is being developed by Telix for patients with renal (kidney) cancer using positron emission tomography (PET) imaging.

Current diagnostics includes MRI or CT scans, which are less sensitive and specific for clear cell renal cell carcinoma, the most common kidney cancer.

Other diagnostic methods include the use of ultrasound guided kidney biopsies, which carries a high risk of procedure complication.

TLX is an antibody-based platform that targets carbonic anhydrase IX, which aids in the conversion of carbon dioxide to carbonic acid, and is highly expressed in several serious cancers, including renal, lung and esophageal.

The Australian patient has been added to the Phase III ZIRCON study.

The Zirconium Imaging in Renal Cancer Oncology (ZIRCON) study is an international multi-centre Phase III study at 25 sites in Europe, Australia, Canada and the Unites States.

ZIRCON is a prospective image trial that currently trialing on approximately 250 renal cancer patients undergoing kidney surgery.

“The study determines the sensitivity and specificity of TLX PET imaging to detect clear cell renal cancer in comparison with histologic “ground truth” determined from surgical resection specimens (removal of diseased organ or area),” the announcement stated.

Telix is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radio-pharmaceuticals.

CEO Dr Christian Behrenbrunch is thankful for the staff and patients at the ONJ Centre.

“As a Melbourne-headquartered biotech company it is a privilege to work with world-class clinical sites in our backyard, and the ONJ Center is a very special place to do clinical research,” he said.

Telix Pharmaceuticals is up 1.13 per cent today and is currently selling at $1.35 per share.

TLX by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening